Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
David Re "Incyte has sales in excess of $1bn p.a and they've never made a prfit, although like us, they are due to have positive numbers within the next few years" Sorry, but that's wrong. Incyte have turned a profit in 2015 and 2016. Admittedly the profit in 2015 was tiny, but they made 104 million USD in 2016, giving an eps of about 55 cents. I don't know where you're getting your info from for Incyte, but it's a couple of years out of date mate BB
Alf Fair answer. The whole RP is just how he is, and I think everyone knows that the chance of enough shareholders getting together to make any sort of impact is highly unlikely, so I think it's best just to let people let off steam if they want to, and then move on, especially if they're posting on another web site ! The BoD are well paid and should be happy enough to take criticism for any shareholders that turn up to an AGM. As for Mission, I'm generally holding between 20 and 25 stocks and comment on pretty much all of them over on iii, but rarely post on any of them on here, mainly because I prefer the blue side. Also, there's not much to say about them. Decent company, well run nice divi, seems undervalued, and that's about it, which is about the limit of what i've said at http://www.iii.co.uk/investment/detail?display=discussion&code=cotn:TMMG.L&it=le in the last twelve months or so ! BB
Alf While I agree with you on what you can get out of an AGM, how come you'd happily go to a Mission one, but not a Provexis one ? I'm a shareholder in Mission as well and noticed a few months ago you saying you'd like to get along to an AGM one day ( www.lse.co.uk/markets/shareprice/chat.asp?share=tmmg ) and meet a few folks. That's really all the likes of Kievsky are saying, they want to meet a few shareholders and talk to the board. No big deal really, and if it's good enough for Mission shareholders, how come you feel the need to denigrate Provexis shareholders going along to theirs ? BB For the record, I won't be going either.
Ah, sorry to hear that Davey. I don't know why, but I had you down as being mid-thirties or something like that. Although we're all invested here primarily to make money, it's also good to know that the company's work is likely to make a real positive difference to peoples lives who are victims of a horrible disease. BB
Davey Haha, I know what you mean about obsession, my partner reckons I'm a bit obsessed with Chi-Med too ! You been married long mate ? BB
Re " but does anyone know our operating costs" Strange question. They were ~2.2 million for 2016 and ~2.1 million for 2015, so they'll likely be between 2.2 and 2.4 million for 2017. Re "Further funding required" Yea, I'd agree with that, at current cash burn rates, some time in 2018 seems most likely for that. To be fair though, the last time they went to the market they raised funds at, or about, whatever the sp was at the time and I'd expect the same to happen next time round too. BB I've no financial interest here one way or the other
Gixer No worries and I agree with you on the focus on UK markets. It matters not one jot where DSM sell Fruitflow, so long as they sell enough, or look likely to sell enough, to convince people that Provexis shares are worth holding or buying, I ain't that bothered. I mean, I'd like people to know about Fruitflow and how it could help them stay healthy, but that'll happen regardless of whether or not I'm seeing a profit here, so that's more of a bonus really. Small, niche companies aren't going to result in much revenue coming our way Alf, so I don't really care about them. Call me old fashioned / blinkered or just stupid if you like, and if you think they're worth getting excited then more power to your elbow, but file me under NEA about them. BB
Gixer You're not really helping with this info ! Of the 11 you've listed, only Healthspan and TheHealthStore are companies which you could describe as having any sort of clout. The others are, if we're being honest, pretty meaningless. I understand you want to defend Provexis against the trolling from Squidbaby, but listing stuff like that is actually counterproductive. From an investment point of view here the story is really more about potential, counteracted by probability of success. From a trading point of view it's more about possible sp rises ( or falls ) caused by news or rumour which may, or may not eventually flow into fundamentals. In both cases, it's not about some products from tiny companies. BB
While fonters may only have come here because Alf's got his back up on the Worthington board, it's still a fair question. IF things didn't take off in China, then it's unlikely to be the end for Provexis. Along with the argument about valuation against net assets, it's by far the whole story and, as Gixer says, the value of the company is much more to do with the value of the IP as it is the sales or profit share. For sure, it's a "jam tomorrow" situation and no-one, if they were being honest, could say hand on heart that our revenue will ever definitely grow to match a 10 million valuation, but, in that respect, it's like a lot of other AIM companies, so you pays your money and takes your pick. As recently as a couple of weeks ago, DSM mentioned Fruitflow, along with four or five other products, in their Q2 presentation ( see https://www.dsm.com/content/dam/dsm/cworld/en_US/documents/presentation-to-investors-q2-2017.pdf ) ****** Nutrition | Outpacing market growth through sustainable solutions in Human Nutrition In line with Nutrition Strategy 2018, Human Nutrition is growing profitably by expanding its core, creating new products and solutions, by growing in underpenetrated categories/ regions, and by accessing new segments/ new business models, all via innovative, sustainable solutions Natural ingredients with specific health benefits such as: – Fruitflow® , contributing to healthy blood flow ... ****** Now that doesn't mean sales will grow enough to get us to break even or to turn a profit, but it does show that DSM still look on it as being important. If a time comes when they stop mentioning Fruitflow, then would be a good time to worry. In the meantime, I'll invest if the price looks right and reduce or sell up if it looks overdone. BB
Alf So they did, I must confess I missed that ! SiS only really came up on my radar after noticing some minor disposal of options by your Marketing Director The date was July 20th though, which should keep GCCR happy :) UK and Europe are expected to be operationally profitable ( EBITDA ) this year, which should give some indication of how the RotW will be in a few years time. You still hopeful of a takeover here ? BB
You'll likely get a trading update next month. There's been one in July for the last couple of years
I only have room for one house builder in my portfolio Strictly, and, for a variety of reasons, including debt, geographic spread and a relatively conservative management, I chose Bellway. Other builders have probably outperformed us over five years or so, but I'm comfortable with the risk/reward ratio here. BB
Don't knock quiet boards Strictly. Some companies just get on with being successful and fly under the radar BB - a shareholder for years - though I did reduce a few months ago, because I thought growth waa slowing. How wrong I was !
Alf I'm informed by a reliable source* that the details of the fund raising via Primary Bid and the EIS will be announced on Monday. BB *Tiddles the cat
Alf Fair does, you reeled me in hook, line and sinker :( As for selling FF+ via Amazon and the dosage / number of tablets, I can't say I was going to lose any sleep over it. Until such time as there's something to drive traffic towards Amazon / FF+ the only people likely to see the page are shareholders. I'd imagine any planned online marketing strategies will have links both to our site and the Amazon page to give people the choice of buying via Amazon ( a trusted brand ) as opposed to a site they've never heard of. BB
Those two PME's resulted in forty eight quids worth of shares being traded Alf. Now, if they'd have resulted in 48k's worth of shares being traded then you might be onto something, but, almost without fail, for years, PME's on Provexis have resulted in nothing newsworthy. Mind you, we are due news on Primary Bid so, if we get an RNS tomorrow then, for once, probably by chance, there'd be a correlation. If we don't, then I trust you'll be piling in tomorrow morning , at a price higher than what you'll like have to pay via Primary Bid ? :) BB
In 2012, 7.8% of US adults used fish oil/Omega3 products https://nccih.nih.gov/research/statistics/NHIS/2012/natural-products/omega3 i think it's dropped a bit since then, but if Fruitflow ever gets close to that sort of uptake then I'll be delighted The market in the UK for fish oils is > £100 million, again, if we ever get near that sort of figure, I'll be very happy BB
Yea, it does look like there's some year-end shuffling going on. Bantam was in for about a million shares btw. As for the order numbers, after last time, I'm not making any guesses ! If the total revenue for the nine to ten months is in the order of 25 to 30k, then the "divide by three" rule is probably about right, but, unless they give us the sales figure in any trading update / info on fund raising, then I doubt we'll get that info till September. BB
https://www.trustnet.com/Investments/Article.aspx?id=200607310700359398G
Davey If memory serves me right then Slater would have to start reducing once Chi-med breached the 10% by value of his fund. As of the end of Jan Chi-Med waa a bit over 6% of his growth fund so, a quick mental calculation suggests the sp would have to rise to 34 or 35 quid before it became an issue. I'm not totally sure about the 10% threshold of a fund though, but it does ring a bell from when he reduced a little while ago. BB